Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
- PMID: 32409208
- DOI: 10.1016/j.jhep.2020.03.016
Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?
Keywords: Hepatocellular carcinoma; Radiofrequency ablation; Sorafenib; Stereotactic body radiation therapy.
Conflict of interest statement
Conflict of interest The author declares no conflict of interest. Please refer to the accompanying ICMJE disclosure forms for further details.
Comment in
-
Reply to: "Can sorafenib use influence outcome when comparing stereotactic body radiation therapy with radiofrequency ablation in patients with hepatocellular carcinoma?".J Hepatol. 2020 Aug;73(2):468-469. doi: 10.1016/j.jhep.2020.04.016. Epub 2020 May 25. J Hepatol. 2020. PMID: 32467075 No abstract available.
Comment on
-
Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.J Hepatol. 2020 Jul;73(1):121-129. doi: 10.1016/j.jhep.2020.03.005. Epub 2020 Mar 10. J Hepatol. 2020. PMID: 32165253
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
